Ignite Creation Date:
2025-12-25 @ 5:05 AM
Ignite Modification Date:
2026-02-22 @ 3:56 PM
Study NCT ID:
NCT06550518
Status:
COMPLETED
Last Update Posted:
2024-08-13
First Post:
2021-06-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Real-life Second-line Epirubicin-Paclitaxel Regimen as Treatment of Relapsed Small-Cell Lung Cancer : EpiTax Study.
Sponsor:
University Hospital, Brest
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
29BRC21.0086 - EPITAX
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None